Acumen Pharmaceuticals (NASDAQ:ABOS) announced that on March 13, 2026 it agreed to sell 10,833,331 common shares at a price of $3.30 each in a private placement with institutional accredited investors. The transaction is expected to generate gross proceeds of roughly $35.75 million, which the company plans to use to support development of its Enhanced Brain Delivery (EBD) program as well as general corporate activities.
The financing, led by RA Capital Management, is scheduled to close on or around March 16, 2026. The agreement includes standard purchase and registration rights provisions and places temporary limitations on the company’s ability to issue additional shares.
Separately, on March 16, 2026, the company reported new preclinical findings from its transferrin-receptor-targeting EBD platform, which is being developed in collaboration with JCR Pharmaceuticals using its J-Brain Cargo technology. Data from in vitro studies, in vivo models, and non-human primate testing showed brain exposure levels between 14 and 40 times higher than those achieved with conventional antibodies, while also demonstrating a low risk of anemia and stability compatible with subcutaneous administration.
Acumen plans to submit an Investigational New Drug (IND) application for its lead EBD clinical candidate by mid-2027. The company believes the platform could help establish a differentiated—and potentially best-in-class—approach within the competitive field of antibody therapies for Alzheimer’s disease, while the new capital provides a clearer funding path to advance its pipeline.
More about Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target toxic soluble amyloid beta oligomers, which are believed to play a key role in Alzheimer’s disease.
Based in Newton, Massachusetts, the company is currently advancing its lead monoclonal antibody candidate, sabirnetug, in a Phase 2 clinical trial. It is also developing next-generation delivery approaches, including subcutaneous formulations and enhanced brain delivery systems, through collaborations such as its partnership with JCR Pharmaceuticals.
Acumen’s research strategy centers on oligomer-selective antibodies and advanced delivery technologies designed to improve drug penetration into the central nervous system and enable more convenient dosing for patients. The company aims to develop disease-modifying treatments for early symptomatic Alzheimer’s disease, positioning itself within a rapidly evolving and highly competitive neurodegenerative therapy market.